(as of 9/1/2021)
AseptiScope Inc.®, an innovative medical device company guided by market driven science, was founded in 2016 by clinical market experts and leading clinicians. Our mission is to develop, manufacture and commercialize novel solutions to address the challenges of healthcare associated infection (HAI). The AseptiScope DiskCover System™, launching in 2020, is the first true barrier solution to address the issue of stethoscope contamination.
Biovista delivers custom drug repositioning, drug de-risking and clinical hold solutions for the Biopharma Industry. Biovista also develops powerful platform technologies for Life science and Biotechnology companies. Biovista has an ongoing R&D program to develop new and improve existing products and services.
We are a British company established in 2010 with the goal of improving the efficiency and safety of minimally invasive surgery through the development and commercialisation of products that maintain uncompromised surgical vision. The OpClear platform, launched in 2013, shields the laparoscope’s lens from condensation and particulates through an intelligent CO2 flow at its tip and removes visual obstructions with an on demand CO2 and saline lens wash, allowing procedures to continue with minimal disruption. Cipher Surgical is focused on research and development, investing 35% of expenditure annually on product advancements. Projects include clinical research to validate the impact of the OpClear platform on patient outcomes. This work enables physicians and hospitals to make evidence-based decisions. Our goal is to make in-situ lens cleaning the standard of care by scientifically demonstrating its true value to healthcare systems worldwide.
Entac Medical is a predictive analytics/AI company developing noninvasive devices for predicting downstream medical adverse events based on a novel, patented platform technology, Previs Audio Spectral Analysis. The first application, PrevisEA, is a noninvasive, disposable, self-contained device demonstrated in three clinical trials to predict gastrointestinal impairment (GII) in surgical patients. Predicting GII is a $2 billion global market in major abdominal surgery alone. PrevisEA received a FDA 510(k) clearance in August 2021 and closed on a $4 million Series B round. Entac will commence a Series C round for PrevisEA commercialization in the near term.
Feldan Therapeutics is a pre-clinical biotechnology company developing leading-edge treatments based on its proprietary peptide-based delivery technology, the Feldan Shuttle platform. The Shuttles can introduce a wide range of cargos intracellularly in different organs including the skin, eyes, and lungs. Feldan is currently developing a topical treatment for Gorlin Syndrome, a rare disease leading to the growth of basal cell carcinomas, with the goal of reaching phase I/II clinical trial in 2022. In parallel to its in-house development, Feldan is also co-developing top-of-the-line applications with biotechs and pharmas. In Q3 2018, Feldan raised $14M in its series A round of VC financing and is looking to close its series B round in 2021.
Imaginostics is a Boston-based health tech startup developing revolutionary magnetic resonance imaging (MRI) biomarkers for the early diagnosis of complex diseases, such as Alzheimer’s Disease and Related Dementias. The company’s proprietary QUTE-CE MRI software suite is a breakthrough in precision medicine that works with existing MRI scanners. Data can be used to stratify patient populations, provide early preventative diagnostics, and assess drug efficacy in clinical trials.
Intrommune Therapeutics is a New York City-based biotechnology company dedicated to transforming and protecting the lives of people with food allergy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste, representing a new therapeutic approach for the treatment of peanut and other food allergies. Called oral mucosal immunotherapy (OMIT), it is designed to address a significant health care need in the industrialized world, where the spread of food allergies has been characterized as an “epidemic.”
LifeOmic’s mission is to use technology, science and data to help individuals improve their health trajectory across the entire continuum - from treating the most complex cancers to prevention and wellness. We achieve this mission by delivering: A cloud and mobile platform that activates precision health to providers, pharmaceutical companies and biotech firms. A suite of consumer mobile apps that deliver healthy interventions to nearly 4 million people worldwide – with efficacy that is better than Omada, Livongo and Noom. An engaging and differentiated employee wellness solution based on our mobile apps and cloud platform to employers of every size – including the underserved SMB market.
NanoView Biosciencesenables life science researchers to better understand the biological role of exosomes and viral vectors and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The company’s proprietary product, the ExoView® platform, is designed to specifically detect and fully characterize exosomes and viral vectors for use in basic and translational research, enabling the development of diagnostic and therapeutic products for nanomedicine.
Patia is a biotechnology company focused on the development, distribution and merchandising of diagnostic tests based on genomics and personalisation of medicine along with digital tools, apps and wearables, in the care of type 2 diabetes and gestational diabetes.
Pixel Technology is a healthcare IT company with over 200 clients - hospitals, with 42 data scientists & developers developing solutions based on artificial intelligence in the following areas: neurology (Neuro AI), in early detection of Multiple Sclerosis (MRImmuno), mammography (Mammo AI), pulmonology (Pulmo AI) and cardiology (Cardio AI).
SageMedic is an early cancer diagnostic company to bring precision medicine to the next level by overcoming the inherent limitations of genomic testing. This breakthrough technology is called the SAGE Direct Test and it faithfully replicates the patient's individual cancer in a live ex-vivo 3D micro-tumor assay with a readout for oncologist within one week. SageMedic's Series A raise will be used to start clinical trials and to provides impact investors with the opportunity to make a bigger impact for cancer patients than any drug currently in development while providing the possibility of a respectiable exit multiple.
SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its proprietary and differentiated sustained-release platform technology. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. The company’s lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for lumbar radiculopathy.
Tactical Therapeutics™, Inc is a clinical stage private company in New York, NY, developing its patented small molecule, a first-in-class inhibitor of non-voltage dependent calcium signaling and multi-kinases, for the treatment of glioblastoma (GBM) and other solid cancers. Proof-of-concept was observed in Phase 1B in 42 GBM patients, with 62% overall survival at 24 months. CTO has the Orphan drug designation for malignant gliomas and is expected to be on the fast-track approval. CTO is being repurposed to prevent SARS-C0V-2 infection and treat COVID-19 disease based on early results.
Our patented telemedicine solution is designed for travelers to keep themselves alive and stable until professional medical care arrives. It maximizes the chances of survival during the crucial time between a medical crisis and emergency room care by integrating our patented features with medical grade sensors in a unified system that allows remote medical personnel to provide uninterrupted personalized care.
We are a clinical-stage biotechnology company developing novel cell therapies to treat solid tumors and infectious disease and to improve bone marrow transplants. Our therapies are powered by our TBX-4000 platform technology which utilizes our proprietary TAT-MYC fusion. Our lead product, TBX-3400, is currently being evaluated in two phase I/II clinical trials targeting patients with advanced or relapsed/refractory melanoma and solid tumors. To-date, we have treated a total of 28 patients and interim results show that TBX-3400 is safe and well-tolerated by patients. And while still early in our clinical trials, there have been clear signs of efficacy based on CT scan and irRECIST criteria.
We are currently raising up to $25 million to fund our clinical trials and to position us for our first exit within the next 12 months.
Tetra Bio-Pharma Inc. is a late-stage biopharmaceutical company with FDA and Health Canada authorized clinical trials that is leading transformational change in identifying and commercializing new molecular entities for pain and inflammation. Tetra uses its unmatched scientific knowledge, regulatory expertise, and decades of peer reviewed research to fuel a robust pipeline of regulated drug candidates indicated in breakthrough pain, cancer pain and Chemotherapy-Induced Nausea and Vomiting. In addition, the Company has one New Drug Application under review with Health Canada and developed an innovative drug that is ready for clinical trials in Acute Respiratory Distress Syndrome, SARS-Cov-2, or Sepsis.
Thrive Bioscience, located in the Boston, MA area, offers customers a family of instruments and software that provide imaging, analytics and automation for reproducible cell culture. Our products empower biologists by combining microscopy, robotics, and software to acquire, organize, and analyze images of their cells.
True Digital Surgery, Inc. based in Goleta, California, is a commercial-stage Medical Technology company developing and commercializing advanced digital surgical visualization technologies. The company's game changing digital robotic-enabled microscopy technology poised to disrupt the surgical microscopy landscape – the technology has unique features and benefits relative to legacy analog and other digital products to enhance surgeon experience, improve patient outcomes and generate significant economic savings for the healthcare system. The company is seeking up to $50 million of Series C growth capital to drive commercial execution and accelerate R&D pipeline efforts to expand addressable market opportunities.
VitalTech is changing the way healthcare is delivered. VitalTech is the first true virtual care delivery platform. VitalCare iQ’s advanced analytics engine and adaptive solutions drive proactive and predictive healthcare insights to support the individual needs of each patient. Practitioners can assign customized care plans by disease state or population, and actionable insights are shared with stakeholders, encouraging proactive, patient-centered care models. Critical data is collected in the patient’s home, aggregated on the VitalCare App, and pushed to our HIPAA-compliant VitalCare iQ cloud. Health systems, concierge medicine groups, home health providers and doctors are all using VitalCare, supported financially by CMS reimbursement, to simplify workflows and remove the complexities of deploying remote patient care.